Diane C. Young Sells 45,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) SVP Diane C. Young sold 45,000 shares of Celldex Therapeutics stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $35.26, for a total value of $1,586,700.00. Following the completion of the transaction, the senior vice president now owns 2,115 shares of the company’s stock, valued at $74,574.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $36.43 on Friday. The firm has a market capitalization of $2.40 billion, a PE ratio of -12.78 and a beta of 1.47. Celldex Therapeutics, Inc. has a 1-year low of $22.11 and a 1-year high of $53.18. The business’s fifty day moving average price is $37.86 and its two-hundred day moving average price is $38.82.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities research analysts expect that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on CLDX. Guggenheim lifted their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Wolfe Research initiated coverage on shares of Celldex Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $51.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Monday, June 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $63.00.

View Our Latest Analysis on Celldex Therapeutics

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. increased its position in Celldex Therapeutics by 13.2% in the 3rd quarter. Principal Financial Group Inc. now owns 12,848 shares of the biopharmaceutical company’s stock valued at $354,000 after acquiring an additional 1,497 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 821 shares during the period. Swiss National Bank increased its holdings in shares of Celldex Therapeutics by 1.0% during the third quarter. Swiss National Bank now owns 88,300 shares of the biopharmaceutical company’s stock valued at $2,430,000 after purchasing an additional 900 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Celldex Therapeutics by 3.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock valued at $9,950,000 after purchasing an additional 10,818 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in Celldex Therapeutics by 9.4% in the third quarter. Deutsche Bank AG now owns 37,221 shares of the biopharmaceutical company’s stock worth $1,024,000 after purchasing an additional 3,213 shares during the period.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Featured Articles

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.